Tencent and Unilever Ventures returned for a round valuing the accounting and invoicing platform developer at nearly $600m.
Author: Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the Global Venturing Review podcast.
XREX gets $17m funding transfer
SBI Group, E.Sun, Systex and AppWorks all contributed to the crypto trading technology provider’s pre-series A round.
OPay charges to $400m round
SoftBank’s Vision Fund 2’s first investment in Africa is set to help the mobile payment app expand its reach.
Kuaikan Manhua sketches $240m in series F
The comics app developer has reached unicorn status through a series F round backed by Tencent and One Store.
Ekuaibao collects $154m in series D
SoftBank’s Vision Fund 2 contributed to the e-invoicing company’s series D round.
Ionova nets $100m
The oncology drug specialist has secured $100m from investors including existing shareholder Lilly Asia Ventures.
QuintoAndar lists another $120m
With backing from Tencent, the online real estate platform has pushed its series E round to $420m.
Metanet Tplatform uplinks with $100m investment
Metanet’s cloud integration subsidiary is getting a $100m boost to accelerate its offerings and expand its footprint.
JustCo gets $74m injection
The co-working space provider secured additional capital from Daito Trust to further expand across Asia Pacific.
MobileCoin ledgers $66m series B
Cryptocurrency exchange Coinbase’s corporate venturing arm is among the investors set to boost the payment platform’s expansion.
NewLink zaps on $308m
The Nio and Xiaomi-backed EV charging platform has added another tranche to its series E round, bringing it to $608m.
Fontinalis wraps up $104m fund
With backing from Ford and unnamed corporates, the mobility-focused venture capital firm has closed its third investment vehicle.
Vigil scoops up $90m in series B
The Amgen-backed neurodegenerative disease treatment specialist is set to fund new medical studies.
GSK Next sets up healthcare incubator
Backed by one of the biggest names in pharma, the studio looks to shake up consumer healthcare markets